Qyuns Therapeutics Unit Passes EU Qualified Person Audit; Shares Down 8%

MT Newswires Live

Oct 13

Qyuns Therapeutics (HKG:2509) said its unit Jiangsu Cellularforce Biopharma has successfully passed the EU Qualified Person audit, confirming that its industrialization base meets European Union Good Manufacturing Practice standards, according to an Oct. 10 Hong Kong bourse filing.

Shares of the firm were down over 8% in Monday afternoon trade.

The audit, conducted over three days by a senior EU QP under EudraLex Volume 4 guidelines, recognized the unit's high-quality management system, advanced facilities, and technical capabilities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575642167"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575642167\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575642167?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 13:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575642167","market":"us","top_or_hot":-1,"title":"Qyuns Therapeutics Unit Passes EU Qualified Person Audit; Shares Down 8%","media":"MT Newswires Live","content":"<html><body><p> Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2509) said its unit Jiangsu Cellularforce Biopharma has successfully passed the EU Qualified Person audit, confirming that its industrialization base meets European Union Good Manufacturing Practice standards, according to an Oct. 10 Hong Kong bourse filing.</p><p>Shares of the firm were down over 8% in Monday afternoon trade.</p><p>The audit, conducted over three days by a senior EU QP under EudraLex Volume 4 guidelines, recognized the unit's high-quality management system, advanced facilities, and technical capabilities.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Unit Passes EU Qualified Person Audit; Shares Down 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Unit Passes EU Qualified Person Audit; Shares Down 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-13 13:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2509) said its unit Jiangsu Cellularforce Biopharma has successfully passed the EU Qualified Person audit, confirming that its industrialization base meets European Union Good Manufacturing Practice standards, according to an Oct. 10 Hong Kong bourse filing.</p><p>Shares of the firm were down over 8% in Monday afternoon trade.</p><p>The audit, conducted over three days by a senior EU QP under EudraLex Volume 4 guidelines, recognized the unit's high-quality management system, advanced facilities, and technical capabilities.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4156","symbol_name":"煤与消费用燃料","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2575642167","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575642167","pubTimestamp":1760333702,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Qyuns Therapeutics  said its unit Jiangsu Cellularforce Biopharma has successfully passed the EU Qualified Person audit, confirming that its industrialization base meets European Union Good Manufacturing Practice standards, according to an Oct. 10 Hong Kong bourse filing.Shares of the firm were down over 8% in Monday afternoon trade.The audit, conducted over three days by a senior EU QP under EudraLex Volume 4 guidelines, recognized the unit's high-quality management system, advanced facilities, and technical capabilities.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4156":"煤与消费用燃料","BK1161":"生物科技","BK4539":"次新股","BK4139":"生物科技","LENZ":"Therapeutics","02509":"荃信生物-B","BK4007":"制药"},"translate_title":"Qyuns Therapeutics部门通过欧盟合格人员审核；股价下跌8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1,"LENZ":1.5},"content_text":"Qyuns Therapeutics (HKG:2509) said its unit Jiangsu Cellularforce Biopharma has successfully passed the EU Qualified Person audit, confirming that its industrialization base meets European Union Good Manufacturing Practice standards, according to an Oct. 10 Hong Kong bourse filing.Shares of the firm were down over 8% in Monday afternoon trade.The audit, conducted over three days by a senior EU QP under EudraLex Volume 4 guidelines, recognized the unit's high-quality management system, advanced facilities, and technical capabilities.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}